Results 61 to 70 of about 22,236,668 (323)
Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly
Junling Zhuang +12 more
doaj +1 more source
Importance The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is ...
B. Shankar +16 more
semanticscholar +1 more source
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira +9 more
core +1 more source
Rare levetiracetam-related adverse events in treatment of epilepsy
The article systematizes data on rare levetiracetam-related adverse events that go beyond the approved data provided in package insert. The key factor in selecting an antiepileptic drug is the risk-benefit ratio, which is largely determined by the ...
T. V. Melashenko +5 more
doaj +1 more source
A retrospective analysis of non–small cell lung carcinoma patients treated with pembrolizumab found that treatment-related adverse events predicted improved clinical outcome.
A. Lisberg +25 more
semanticscholar +1 more source
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
Background. Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. Methods.
Hye Duck Choi, Ji Hae Kim
doaj +1 more source
Management of immune checkpoint inhibitor‐related rheumatic adverse events
Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients ...
Jiaxin Zhou +10 more
doaj +1 more source
Treatment-related adverse events during the 188-week extension phase.
Treatment-related adverse events during the 188-week extension phase.
Gunnar Buyse (503776) +9 more
core +1 more source
Associated costs and disutility of grade ≥ 3 treatment-related adverse events.
Associated costs and disutility of grade ≥ 3 treatment-related adverse events.
Lingyuan Chen (15457274) +3 more
core +1 more source
Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine +17 more
wiley +1 more source

